Eton 10-Q: Q3 Sales $57.9M, Nine-Month Operating Cash Flow $49.9M, Cash Builds to $55.6M
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton's Q3 10-Q confirms $57.9 million of product sales, $49.9 million of nine-month operating cash flow and $55.6 million of cash, with net income boosted by a $12.9 million non-cash tax valuation allowance release.
Key Events · Earnings and Guidance · ETON
-
Q3 Product Sales $57.9M, Up 158%
Third-quarter net product sales were $57,925 thousand versus $22,459 thousand a year earlier, driven by the February 2026 HEMANGEOL acquisition and growth across INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, DESMODA and Carglumic Acid.
-
Nine-Month Operating Cash Flow $49.9M
Net cash from operating activities reached $49,901 thousand for the nine months versus $22,075 thousand in 2025, funding $18,225 thousand of product license purchases and $8,000 thousand of debt repayment while cash rose to $55,628 thousand.
-
Net Income Inflated by Tax Benefit
Q3 net income of $35,249 thousand includes a $12,892 thousand non-cash release of a deferred tax valuation allowance; non-GAAP diluted EPS was $0.50 versus GAAP diluted EPS of $1.06.
-
Debt Cut to $23.1M Net
The SWK/Runway facility was reduced by $8,000 thousand of principal payments including a $5,000 thousand prepayment; $3,000 thousand quarterly principal payments begin November 2026 with $7,000 thousand due at December 2027 maturity.
Analysis · ETON · Life Sciences
The headline numbers were already out this evening via the 8-K, but the 10-Q is where the balance sheet and cash generation become verifiable. Nine-month operating cash flow of $49.9 million against $22.1 million a year earlier, plus $55.6 million of cash after $18.2 million of product-rights purchases and $8.0 million of debt repayment, shows the business now funds its own deal-making. The $35.2 million Q3 net income is flattered by a $12.9 million non-cash release of a deferred tax valuation allowance; non-GAAP diluted EPS was $0.50. Watch the $3,000 thousand quarterly principal payments starting November 2026 and the $10 million LIBERVANT upfront paid in October, which will draw on that cash in Q4.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETON was trading at $57.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $14.27 to $66.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.